I'm LongbridgeAI. Here is the key information I extracted- The company raised its full - year revenue guidance to 62.0 billion to 64.0 billion dollars and adjusted EPS guidance to 2.95 to 3.05 dollars.…
Pfizer (PFE.US) climbed nearly 3% during regular trading to $30.77.
The pharmaceuticals industry index rose 2.4% over the same period.
The company reported fiscal third-quarter revenue of $16.58 billion, topping the analyst consensus of $15.87 billion. Adjusted earnings per share came in at $0.87, beating estimates of $0.73. Operational revenue grew 7% excluding Covid-19 products, while sales from launched and acquired non-Covid assets surged 32%. Pfizer raised its full-year revenue guidance to $62.0 billion to $64.0 billion and adjusted EPS outlook to $2.95 to $3.05, up from prior ranges of $60.5 billion to $62.5 billion and $2.80 to $3.00, respectively.
Citi raised its price target on Pfizer to $30 from $27, while RBC increased its target to $28 from $25. Management said on the earnings call that cost savings will be reinvested into R&D with a focus on oncology and obesity pipelines, targeting approval for a monthly weight-loss injection by 2028. Nearly all of the expected $7.2 billion in net savings are on track to be realized by end-2026.
Based on public media reports. AI-generated; not investment advice.
